169 related articles for article (PubMed ID: 38440808)
1. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract][Full Text] [Related]
2. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
Troussard X; Maître E; Cornet E
Am J Hematol; 2022 Feb; 97(2):226-236. PubMed ID: 34710243
[TBL] [Abstract][Full Text] [Related]
3. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E; Cornet E; Troussard X
Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
[TBL] [Abstract][Full Text] [Related]
4. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
Troussard X; Cornet E
Am J Hematol; 2017 Dec; 92(12):1382-1390. PubMed ID: 29110361
[TBL] [Abstract][Full Text] [Related]
5. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
Cornet E; Delmer A; Feugier P; Garnache-Ottou F; Ghez D; Leblond V; Levy V; Maloisel F; Re D; Zini JM; Troussard X;
Ann Hematol; 2014 Dec; 93(12):1977-83. PubMed ID: 24994538
[TBL] [Abstract][Full Text] [Related]
6. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
7. Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.
Maitre E; Paillassa J; Troussard X
Front Oncol; 2022; 12():1068981. PubMed ID: 36620555
[TBL] [Abstract][Full Text] [Related]
8. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
9. Biology and Treatment of Hairy Cell Leukemia.
Paillassa J; Troussard X
Curr Treat Options Oncol; 2020 Apr; 21(6):44. PubMed ID: 32350628
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system.
Naseem S; Gupta O; Binota J; Varma N; Varma S; Malhotra P
Mol Biol Rep; 2020 Jun; 47(6):4365-4372. PubMed ID: 32458259
[TBL] [Abstract][Full Text] [Related]
11. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
13. Bone marrow and splenic histology in hairy cell leukaemia.
Wotherspoon A; Attygalle A; Mendes LS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):200-7. PubMed ID: 26614898
[TBL] [Abstract][Full Text] [Related]
14. Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.
Maitre E; Tomowiak C; Lebecque B; Bijou F; Benabed K; Naguib D; Kerneves P; Cornet E; Viailly PJ; Arsham J; Sola B; Jardin F; Troussard X
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454811
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
Falini B; Martelli MP; Tiacci E
Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
[TBL] [Abstract][Full Text] [Related]
16. New insights in the management of patients with hairy cell leukemia.
Cornet E; Damaj G; Troussard X
Curr Opin Oncol; 2015 Sep; 27(5):371-6. PubMed ID: 26154707
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic options for relapsed hairy cell leukemia.
Jain P; Polliack A; Ravandi F
Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
[TBL] [Abstract][Full Text] [Related]
19. Update on hairy cell leukemia.
Kreitman RJ; Arons E
Clin Adv Hematol Oncol; 2018 Mar; 16(3):205-215. PubMed ID: 29742076
[TBL] [Abstract][Full Text] [Related]
20. Hairy cell leukaemia with unusual BRAF mutations.
Maitre E; Macro M; Troussard X
J Cell Mol Med; 2023 Sep; 27(17):2626-2630. PubMed ID: 37530550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
